Key result
Intravenous tirofiban infusion significantly reduced the frequency of postprocedural abnormal cTn-I levels compared to standard therapy in patients undergoing elective PCI (16% vs 37%, p=0.017).
Why the study?
Does intravenous tirofiban infusion reduce minor myocardial injury (cTn-I and cTn-T elevation) in patients undergoing elective percutaneous coronary intervention?
Population
119 consecutive patients scheduled for elective coronary balloon angioplasty with or without stent…
Comparison
Intravenous tirofiban infusion added to standard… vs Standard therapy alone
Design
RCT, Randomized
Follow-up
24 hours
Authors
Loading...
Supports tirofiban to reduce minor myocardial injury in elective PCI; extends GP IIb/IIIa evidence to lower-risk procedures.
RCT (n=119)
Does intravenous tirofiban infusion reduce minor myocardial injury (cTn-I and cTn-T elevation) in patients undergoing elective percutaneous coronary intervention?
Absolute Event Rate: 16% vs 37%
p-value: p=0.017
Glycoprotein IIb/IIIa inhibition with tirofiban significantly reduces the incidence of minor myocardial injury (troponin elevation) following elective percutaneous coronary intervention.
Ökmen et al. (2004) conducted an RCT in Elective percutaneous coronary intervention (PCI) (n=119). Tirofiban vs. Standard therapy (preprocedural aspirin, ticlopidine, and intravenous heparin) was evaluated on Postprocedural abnormal cTn-I levels (p=0.017). Intravenous tirofiban infusion significantly reduced the frequency of postprocedural abnormal cTn-I levels compared to standard therapy in patients undergoing elective PCI (16% vs 37%, p=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: